Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.77 USD | -0.94% | -1.44% | +11.69% |
Financials (USD)
Sales 2024 * | 167M | Sales 2025 * | 301M | Capitalization | 1.43B |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | 91M | EV / Sales 2024 * | 8.95 x |
Net Debt 2024 * | 66.33M | Net cash position 2025 * | 5.71M | EV / Sales 2025 * | 4.73 x |
P/E ratio 2024 * |
-35
x | P/E ratio 2025 * |
19.8
x | Employees | 154 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 39.35% |
Latest transcript on Avadel Pharmaceuticals plc
1 day | -0.94% | ||
1 week | -1.44% | ||
Current month | +23.40% | ||
1 month | +16.21% | ||
3 months | +13.78% | ||
6 months | +33.08% | ||
Current year | +11.69% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Thomas McHugh
DFI | Director of Finance/CFO | 59 | 19-12-01 |
Scott Macke
COO | Chief Operating Officer | - | 14-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Ende
BRD | Director/Board Member | 55 | 18-11-30 |
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Mark McCamish
BRD | Director/Board Member | 72 | 19-12-04 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 15.77 | -0.94% | 655,482 |
24-03-15 | 15.92 | -1.12% | 685,709 |
24-03-14 | 16.1 | +0.12% | 887,709 |
24-03-13 | 16.08 | +0.69% | 981,013 |
24-03-12 | 15.97 | -0.19% | 1,440,388 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.69% | 1.43B | |
+30.83% | 687B | |
+30.96% | 595B | |
+0.01% | 378B | |
+15.18% | 316B | |
+11.39% | 308B | |
+0.78% | 211B | |
-6.09% | 208B | |
-2.92% | 203B | |
-3.72% | 157B |